Zobrazeno 1 - 10
of 359
pro vyhledávání: '"Lung Neoplasms/pathology"'
Publikováno v:
BMC Medical Imaging, Vol 23, Iss 1, Pp 1-16 (2023)
Abstract Medical image processing has proven to be effective and feasible for assisting oncologists in diagnosing lung, thyroid, and other cancers, especially at early stage. However, there is no reliable method for the recognition, screening, classi
Externí odkaz:
https://doaj.org/article/3de37980dbd548a897d4760a68f455a6
Autor:
Cormac O’Brien, John A. Duignan, Margaret Gleeson, Orla O’Carroll, Alessandro N. Franciosi, Dermot O’Toole, Aurelie Fabre, Rachel K. Crowley, Cormac McCarthy, Jonathan D. Dodd, David J. Murphy
Publikováno v:
Diagnostics, Vol 12, Iss 12, p 3096 (2022)
Objectives: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) occurs due to abnormal proliferation of pulmonary neuroendocrine cells. We hypothesized that performing a quantitative analysis of airway features on chest CT may reve
Externí odkaz:
https://doaj.org/article/3e6beb8385924ecdb4622662c11ec349
Autor:
Anne I. Kraemer, Chloe Chong, Florian Huber, HuiSong Pak, Brian J. Stevenson, Markus Müller, Justine Michaux, Emma Ricart Altimiras, Sylvie Rusakiewicz, Laia Simó-Riudalbas, Evarist Planet, Maciej Wiznerowicz, Julien Dagher, Didier Trono, George Coukos, Stephanie Tissot, Michal Bassani-Sternberg
Publikováno v:
Nature cancer, vol. 4, no. 5, pp. 608-628
One key barrier to improving efficacy of personalized cancer immunotherapies that are dependent on the tumor antigenic landscape remains patient stratification. Although patients with CD3+CD8+ T cell-inflamed tumors typically show better response to
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y. C. Gary Lee, Ian M. Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney, Oluf Dimitri Røe
Publikováno v:
Louw, A, Panou, V, Szejniuk, W M, Meristoudis, C, Chai, S M, van Vliet, C, Lee, Y C G, Dick, I M, Firth, T, Lynggaard, L A, Asghari, A B, Vyberg, M, Hansen, J, Creaney, J & Røe, O D 2022, ' BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma : A validation study ', Journal of Thoracic Oncology, vol. 17, no. 7, pp. 921-930 . https://doi.org/10.1016/j.jtho.2022.04.008
INTRODUCTION: Pleural mesothelioma (PM) is an aggressive malignancy with no identified predictive biomarkers. We assessed whether tumor BAP1 status is a predictive biomarker for survival in patients receiving first-line combination platinum and pemet
Publikováno v:
Paulsen, B S, Aggerholm-Pedersen, N & Larsen, A W 2023, ' Pretreatment platelet count is a prognostic marker in lung cancer: A Danish registry-based cohort study ', Clinical Lung Cancer, vol. 24, no. 2, pp. 175-183 . https://doi.org/10.1016/j.cllc.2022.12.012
Background: Thrombocytosis has been associated with a poor prognosis in a wide range of malignancies. However, the results have been conflicting for lung cancer. Therefore, we evaluated the prognostic value of platelet count in a large cohort of lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d13488b47f885388664461502b602e0
https://pure.au.dk/portal/da/publications/pretreatment-platelet-count-is-a-prognostic-marker-in-lung-cancer(9b72da7d-0a1c-4225-a7fe-7724b857cbe7).html
https://pure.au.dk/portal/da/publications/pretreatment-platelet-count-is-a-prognostic-marker-in-lung-cancer(9b72da7d-0a1c-4225-a7fe-7724b857cbe7).html
Publikováno v:
Mughal, H A, Mouritzen, M T, Takacs-Szabó, Z & Szejniuk, W M 2022, ' Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity ', BMJ Case Reports, vol. 15, no. 12, e252590 . https://doi.org/10.1136/bcr-2022-252590
Treatment of induced oligometastatic disease after partial response to systemic antineoplastic therapy in non-small cell lung cancer (NSCLC) remains controversial. The introduction of immune checkpoint inhibitors (ICIs) has revolutionised the treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::468f514d10dc7174442b3f85928cfb45
https://vbn.aau.dk/da/publications/56fb0225-5d58-4fd2-81b5-c97a7f44ea31
https://vbn.aau.dk/da/publications/56fb0225-5d58-4fd2-81b5-c97a7f44ea31
Autor:
Jan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Steven G. Gray, Luca Ampollini, Joachim G. Aerts, Emanuela Felley-Bosco, Michaela B. Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samarzija, Roger Llatjos, Stephen P. Finn, Enrico Silini, Jan von der Thüsen, Nesa Marti, Karerina Vervita, Roswitha Kammler, Solange Peters, Rolf A. Stahel, Paul Baas, Isabelle Opitz, Rolf Stahel, Anita Hiltbrunner, Rosita Kammler, Patrick Vagenknecht, Barbara Ruepp, Urania Dafni, Panagiota Zygoura, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Androniki Stavrou, Jan H. Rüschoff, Susanne Dettwiler, Fabiola Prutek, Christiane Mittmann, Bart Vrugt, Martina Friess, Alessandra Matter, Chloé Spichiger-Häusermann, Eric Verbeken, Birgit Weyenand, Liesbet Peeters, Marcello Tiseo, Enrico Maria Silini, Luigi Ventura, Letizia Gnetti, Paolo Carbognani, Fatemeh B. Zaeimi, Sven Seiwerth, Marko Jakopovic, Felipe Cardenal, Susana Lorente, Konstantinos Syrigos, Ioannis Vamvakaris, Paraskevi Boura, Steven Gray, Mutaz Mohammed Nur, Anne-Marie Baird, Martin Barr, Sinead Cuffe, Kathy Gately, Joachim Aerts
Publikováno v:
Modern Pathology, 35(12), 1888-1899. SPRINGERNATURE
Modern Pathology, 35(12), 1888-1899. Nature Publishing Group
Modern Pathology, 35(12), 1888-1899. Nature Publishing Group
Pleural mesothelioma (PM) is an aggressive malignancy with poor prognosis. Although histology and pathologic stage are important prognostic factors, better prognostic biomarkers are needed. The ribosomal protein S6 is a downstream target of the phosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::355b5c339b724ea833e0f7b1c96df40e
https://doi.org/10.1038/s41379-022-01145-0
https://doi.org/10.1038/s41379-022-01145-0
Autor:
Tapashi Dalvi, Mette Nørgaard, Jon P. Fryzek, Naimisha Movva, Lars Pedersen, Hanh Pham Hansen, Jill Walker, Anita Midha, Norah Shire, Anne-Marie Boothman, James Rigas, Anders Mellemgaard, Torben R. Rasmussen, Stephen Hamilton-Dutoit, Deirdre Cronin-Fenton
Publikováno v:
Dalvi, T, Nørgaard, M, Fryzek, J P, Movva, N, Pedersen, L, Pham Hansen, H, Walker, J, Midha, A, Shire, N, Boothman, A-M, Rigas, J, Mellemgaard, A, Rasmussen, T R, Hamilton-Dutoit, S & Cronin-Fenton, D 2023, ' Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark ', PLOS ONE, vol. 18, no. 4, pp. e0284037 . https://doi.org/10.1371/journal.pone.0284037
Introduction Programmed cell death ligand-1 (PD-L1) expression may help identify patients with non-small cell lung cancer (NSCLC) who would benefit from immunotherapy. We assessed PD-L1 expression, and epidermal growth factor receptor (EGFR) and V-Ki